News articles about Histogenics (NASDAQ:HSGX) have trended somewhat positive on Monday, Accern Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Histogenics earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 45.5897876606545 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
HSGX traded down $0.05 on Monday, reaching $2.75. The company had a trading volume of 2,666 shares, compared to its average volume of 131,670. The company has a market capitalization of $80.32, a P/E ratio of -2.81 and a beta of 1.68. Histogenics has a 52-week low of $1.59 and a 52-week high of $3.35.
Histogenics (NASDAQ:HSGX) last announced its earnings results on Thursday, March 15th. The biotechnology company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.05. research analysts anticipate that Histogenics will post -0.68 EPS for the current year.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3343617/histogenics-hsgx-receiving-somewhat-favorable-press-coverage-report-shows.html.
Histogenics Company Profile
Histogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.